Investigating the role of Izumo1 in maintaining remission in lupus
Official title: Izumo1 in remission in SLE
Funded at Johns Hopkins University · NIH-11031414 · Data updated 2026-11-12
This study is looking at how a specific marker called Izumo1 might help keep lupus symptoms under control during periods when the disease is not active, and it's for people living with lupus who want to learn more about new ways to manage their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | February 8, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $198,547 |
| NIH project number | 5R21AI183113-02 |
| Project ID | NIH-11031414 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who experience periods of remission.
✕Less likely to help
Patients with other autoimmune diseases or those who do not have systemic lupus erythematosus may not benefit from this research.
What this research studies
This research focuses on systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by periods of flare-ups and remission. The study aims to understand the regulatory pathways that are activated during remission, particularly the role of a biomarker called Izumo1. Researchers will analyze a large group of SLE patients to gather clinical and functional evidence regarding Izumo1's potential to reduce inflammation and maintain remission. By identifying how Izumo1 functions, the research could lead to new therapeutic strategies for managing SLE.
Why it matters
Potential benefit: If successful, this research could lead to the identification of a new biomarker and therapeutic approach for sustaining remission in lupus patients.
How similar studies have gone: While the specific role of Izumo1 in SLE remission is novel, similar research approaches have shown promise in identifying biomarkers for other autoimmune conditions.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Andrade, Felipe — Johns Hopkins University
- Study coordinator: Andrade, Felipe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.